If obesity rates continue to increase then the number of cancer cases in the UK could double in the next 40 years, a leading cancer expert has warned ahead of a conference of scientists specializing in the links between cancer and obesity. Martin Wiseman, medical and scientific adviser for World Cancer Research Fund, believes today's children could face big increases in rates of cancer as adults unless something is done to curb the obesity crisis.
Speaking ahead of a London conference organized by the charity and the Association for the Study of Obesity, Prof Wiseman said the fact that a third of women and half of men are projected to be obese in 40 years is one of the most important reasons for the expected doubling in cancer cases.
He said: "the evidence now shows that, after not smoking, maintaining a healthy weight is the most important thing you can do for cancer prevention. This means that if rates of obesity continue to rise then this will have serious consequences for cancer rates in the UK. Unless something happens soon to stop the increase in obesity, then we are sleepwalking towards a situation where the UK will be facing more cancer cases than ever before. Rising obesity rates are not the only reason we expect the number of cancer cases to double over the next 40 years, but it is an important factor."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze